Editas' share price has struggled due to clinical setbacks, but recent focus on in-vivo gene editing offers renewed hope and ...

In July 2025, Novartis Pharmaceuticals announced a phase III study to assess efficacy and safety of crizanlizumab (5 mg/kg) ...

By using a protein called Cas9 to find and remove a damaged portion of a genetic sequence and then replace it using a ...

CRISPR-based innovators like NTLA, EDIT and PRME are gaining traction as genomics reshapes the future of medicine and biotech ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of ...

SkyQuest Technology Consulting published a report, titled, Cell Therapy Market - Global Opportunity Analysis and Industry ...

The US biopharma has planted roots in the UK’s biotech cluster as it bets on synthetic rescue to unlock new treatments for rare diseases.